114 studies found for:    cp18
Show Display Options
Rank Status Study
1 Terminated Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects
Condition: Breast Cancer
Intervention: Radiation: [F18]CP-18 Injection
2 Withdrawn 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
Conditions: Ovarian Neoplasms;   Ovarian Cancer;   Fallopian Tube Neoplasms;   Fallopian Tube Cancer
Interventions: Drug: [18F]-CP18;   Procedure: PET/ CT
3 Completed
Has Results
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: IMC-A12;   Drug: Mitoxantrone;   Drug: Prednisone;   Biological: IMC-1121B (ramucirumab)
4 Recruiting Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: CP-690,550
5 Completed
Has Results
A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age
Condition: Healthy or Stable Underlying Chronic Medical Condition
Interventions: Biological: Q/LAIV (MEDI3250);   Biological: FluMist/B/Yamagata;   Biological: FluMist/B/Victoria
6 Completed
Has Results
A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age
Condition: Healthy or Stable Underlying Chronic Medical Condition
Interventions: Biological: Q/LAIV-BFS (MEDI8662);   Biological: FluMist/B/Yamagata;   Biological: FluMist/B/Victoria
7 Completed
Has Results
Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
Condition: Smoking Cessation
Interventions: Drug: varenicline tartrate (CP-526, 555-18);   Drug: Placebo
8 Completed A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Product
Condition: Healthy Volunteer
Interventions: Drug: Drug Product CP4;   Drug: Drug Product CP2
9 Completed
Has Results
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
Conditions: Philadelphia Chromosome Positive;   Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: Nilotinib
10 Completed
Has Results
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550;   Drug: Placebo
11 Recruiting A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Placebo;   Drug: CP690,550;   Drug: CP-690,550
12 Active, not recruiting Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Squamous Cell Carcinoma of the Esophagus;   Stage II Esophageal Cancer;   Stage II Gastric Cancer;   Stage III Esophageal Cancer;   Stage III Gastric Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: oxaliplatin;   Drug: fluorouracil;   Radiation: radiation therapy;   Procedure: conventional surgery;   Other: immunohistochemistry staining method;   Procedure: positron emission tomography;   Procedure: computed tomography;   Procedure: laboratory biomarker analysis;   Genetic: gene expression analysis;   Radiation: fludeoxyglucose F 18
13 Completed
Has Results
A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: CP-690,550 + methotrexate;   Drug: Placebo + Methotrexate
14 Completed Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
Conditions: Obesity;   Hepatic Insufficiency
Intervention: Drug: CP-945,598
15 Completed Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
Condition: Obesity
Intervention: Drug: CP-945,598
16 Completed Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females
Condition: Prophylaxis HPV-16/18 Infections and Cervical Neoplasia
Interventions: Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1);   Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2);   Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3);   Biological: MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)
17 Active, not recruiting Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Condition: Breast Cancer
Interventions: Biological: Ramucirumab DP;   Biological: IMC-18F1;   Drug: Capecitabine
18 Completed Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy
Condition: Advanced Solid Tumors
Intervention: Biological: IMC-18F1
19 Completed Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females
Condition: Prophylaxis HPV-16/18 Infections and Cervical Neoplasia
Interventions: Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine;   Biological: MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3;   Biological: MEDI-517 HPV-16/18 VLP vaccine without adjuvant
20 Completed A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
Conditions: Colon Cancer;   Rectal Cancer
Interventions: Biological: IMC-1121B;   Biological: IMC-18F1;   Drug: mFOLFOX-6

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years